ID   UM-SCC-47
AC   CVCL_7759
SY   UMSCC-47; UMSCC47; UM-SCC47; UM:SCC047; UMSCC047; University of Michigan-Squamous Cell Carcinoma-47
DR   cancercelllines; CVCL_7759
DR   Cosmic; 1122677
DR   Cosmic; 2131865
DR   Cosmic; 2296309
DR   GEO; GSM937830
DR   GEO; GSM937831
DR   GEO; GSM3631278
DR   IARC_TP53; 21103
DR   Millipore; SCC071
DR   Progenetix; CVCL_7759
DR   Wikidata; Q54990870
RX   PubMed=12884349;
RX   PubMed=17312569;
RX   PubMed=17848307;
RX   PubMed=19760794;
RX   PubMed=21868764;
RX   PubMed=23419152;
RX   PubMed=24201445;
RX   PubMed=25275298;
RX   PubMed=26045983;
RX   PubMed=28196595;
RX   PubMed=28236344;
RX   PubMed=29156801;
RX   PubMed=31541927;
RX   PubMed=32574978;
RX   PubMed=33802339;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Virology: Contains from 21 to 47 copies of the HPV16 genome (PubMed=24201445).
CC   Doubling time: 2.2 days (PubMed=29156801).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly192Ter (c.574G>T); Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349).
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: UPCI:SCC47; GEO=GSM937830; GEO=GSM937831.
CC   Derived from site: In situ; Oral cavity, tongue, lateral border; UBERON=UBERON_0011877.
ST   Source(s): Millipore=SCC071; PubMed=19760794; PubMed=21868764; PubMed=25275298; PubMed=29156801; PubMed=33802339
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 8,11
ST   D16S539: 8,13
ST   D18S51: 18
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 25
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 15
ST   FGA: 23,25
ST   Penta D: 9,10
ST   Penta E: 12,13
ST   TH01: 7,9.3
ST   TPOX: 10,11
ST   vWA: 18
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   PubMed=12884349; DOI=10.1002/hed.10274;
RA   Bradford C.R., Zhu S.-B., Ogawa H., Ogawa T., Ubell M., Narayan A.,
RA   Johnson G., Wolf G.T., Fisher S.G., Carey T.E.;
RT   "P53 mutation correlates with cisplatin sensitivity in head and neck
RT   squamous cell carcinoma lines.";
RL   Head Neck 25:654-661(2003).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=17848307; DOI=10.1016/j.ijrobp.2007.04.082;
RA   Yarbrough W.G., Whigham A., Brown B., Roach M., Slebos R.J.C.;
RT   "Phosphoinositide kinase-3 status associated with presence or absence
RT   of human papillomavirus in head and neck squamous cell carcinomas.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 69:S98-S101(2007).
//
RX   PubMed=19760794; DOI=10.1002/hed.21198;
RA   Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R.,
RA   Lyons R.H., Bradford C.R., Carey T.E.;
RT   "Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell
RT   lines.";
RL   Head Neck 32:417-426(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23419152; DOI=10.1186/gm419;
RA   Lechner M., Fenton T., West J., Wilson G., Feber A., Henderson S.,
RA   Thirlwell C., Dibra H.K., Jay A., Butcher L.M., Chakravarthy A.R.,
RA   Gratrix F., Patel N., Vaz F., O'Flynn P., Kalavrezos N.,
RA   Teschendorff A.E., Boshoff C., Beck S.;
RT   "Identification and functional validation of HPV-mediated
RT   hypermethylation in head and neck squamous cell carcinoma.";
RL   Genome Med. 5:15.1-15.16(2013).
//
RX   PubMed=24201445; DOI=10.1101/gr.164806.113;
RA   Akagi K., Li J.-F., Broutian T.R., Padilla-Nash H.M., Xiao W.-H.,
RA   Jiang B., Rocco J.W., Teknos T.N., Kumar B., Wangsa D., He D., Ried T.,
RA   Symer D.E., Gillison M.L.;
RT   "Genome-wide analysis of HPV integration in human cancers reveals
RT   recurrent, focal genomic instability.";
RL   Genome Res. 24:185-199(2014).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=26045983;
RA   Ziemann F., Arenz A., Preising S., Wittekindt C., Klussmann J.P.,
RA   Engenhart-Cabillic R., Wittig A.;
RT   "Increased sensitivity of HPV-positive head and neck cancer cell lines
RT   to X-irradiation +/- cisplatin due to decreased expression of E6 and
RT   E7 oncoproteins and enhanced apoptosis.";
RL   Am. J. Cancer Res. 5:1017-1031(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28236344; DOI=10.1002/hed.24729;
RA   Walline H.M., Goudsmit C.M., McHugh J.B., Tang A.L., Owen J.H.,
RA   Teh B.T., McKean E.L., Glover T.W., Graham M.P., Prince M.E.P.,
RA   Chepeha D.B., Chinn S.B., Ferris R.L., Gollin S.M., Hoffmann T.K.,
RA   Bier H., Brakenhoff R.H., Bradford C.R., Carey T.E.;
RT   "Integration of high-risk human papillomavirus into cellular
RT   cancer-related genes in head and neck cancer cell lines.";
RL   Head Neck 39:840-852(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//
RX   PubMed=32574978; DOI=10.1016/j.tranon.2020.100808;
RA   Nair T.S., Thomas T.B., Yang L., Kakaraparthi B.N., Morris A.C.,
RA   Clark A.M., Campredon L.P., Brouwer A.F., Eisenberg M.C., Meza R.,
RA   Carey T.E.;
RT   "Characteristics of head and neck squamous cell carcinoma cell lines
RT   reflect human tumor biology independent of primary etiologies and HPV
RT   status.";
RL   Transl. Oncol. 13:100808.1-100808.9(2020).
//
RX   PubMed=33802339; DOI=10.3390/cancers13051069;
RA   Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.;
RT   "Genotyping and characterization of HPV status, hypoxia, and
RT   radiosensitivity in 22 head and neck cancer cell lines.";
RL   Cancers (Basel) 13:1069.1-1069.12(2021).
//